Tempest Therapeutics TPST
Tempest Therapeutics adjourns special meeting
Additional proxy materials
- Form
- DEFA14A
- Filed
- Importance
- Routine
- Accession
- 0001213900-26-111032
- 74.3% of shares present at meeting
- Proposal requires 75% vote for approval
- Meeting reconvened on Nov 12, 2026
- Proxies will be used unless revoked
Written from the DEFA14A on EDGAR. Check the filing before you rely on it.
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- ProMIS Neurosciences PMN public float $30M, Jun 30, 2025
- Provectus Biopharmaceuticals PVCT public float $31M, Jun 30, 2025
- Cumberland Pharmaceuticals CPIX public float $29M, Jun 30, 2025
- Rockwell Medical RMTI public float $29M, Jun 30, 2025
- Champions Oncology CSBR public float $29M, Oct 31, 2025